- Home
- RVNC
as 11-21-2024 11:38am EST
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | NASHVILLE |
| Market Cap: | 599.6M | IPO Year: | 2014 |
| Target Price: | $10.23 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.30 - $9.75 | Next Earning Date: | 11-07-2024 |
| Revenue: | $256,945,000 | Revenue Growth: | 25.82% |
| Revenue Growth (this year): | 20.36% | Revenue Growth (next year): | 31.66% |
Stock Insider Trading Activity of Revance Therapeutics Inc. (RVNC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hollander David | RVNC | CMO & Global Therapeutics Lead | Nov 18 '24 | Sell | $4.17 | 3,908 | $16,296.36 | 104,945 |
Latest Revance Therapeutics Inc. News
RVNC Breaking Stock News: Dive into RVNC Ticker-Specific Updates for Smart Investing
Zacks
14 days ago
Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Lags Revenue Estimates
Business Wire
14 days ago
Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update
MT Newswires
a month ago
Revance Therapeutics, Crown Laboratories Extend Merger Date Amid Commercialization Dispute
Zacks
2 months ago
Down -17.96% in 4 Weeks, Here's Why Revance Therapeutics (RVNC) Looks Ripe for a Turnaround
MT Newswires
2 months ago
Top Premarket Decliners
GuruFocus.com
2 months ago
Beryl Capital Management LLC Acquires New Stake in Revance Therapeutics Inc
MT Newswires
2 months ago
Barclays Downgrades Revance Therapeutics to Equalweight From Overweight, Price Target is $7
GuruFocus.com
2 months ago
Capital World Investors Reduces Stake in Revance Therapeutics
Compare RVNC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RVNC Revance Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.